Literature DB >> 16343603

Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study.

Jacopo Gianetti1, Maria Serena Parri, Silverio Sbrana, Fabrizio Paoli, Stefano Maffei, Umberto Paradossi, Sergio Berti, Aldo Clerico, Andrea Biagini.   

Abstract

INTRODUCTION: An increasing amount of evidence indicates that platelet reactivity, despite a standard anti-thrombotic therapy, is a potential risk factor for recurrent myocardial ischemia in patients with coronary artery disease. We now hypothesize that this condition, measured by collagen-epinephrine (CEPI) or collagen-ADP (CADP) closure times (CT) by Platelet Function Analyzer (PFA-100), may predict the recurrence of coronary events after percutaneous coronary intervention (PCI).
MATERIALS AND METHODS: CEPI and CADP-CT were measured 30+/-8 h after PCI in 175 consecutive patients admitted with a diagnosis of stable angina (n=94) or acute coronary syndromes (n=81) and prospectively followed up for a mean period of 6 months. We stratified the patients in accordance to both the CEPI-CT (<or> 190 s), reflecting the intensity of cycloxygenase inhibition by aspirin and the distribution into quartiles for CADP-CT.
RESULTS: CEPI-CT<190 s as well as CADP-CT<82 s were associated with a higher rate of clinical recurrence (hazard ratio 8.5, p<0.001 and 22.9, p<0.001, respectively). Multivariate analysis after adjustment for other risk factors confirmed that the lowest CADP-CT quartile significantly correlates with the risk of recurrent coronary events (hazard ratio 36.5, p<0.01), as well as CEPI-CT<190 s (hazard ratio 6.7, p=0.01).
CONCLUSIONS: An enhanced platelet function after PCI when measured under high shear rates by PFA-100 is an independent predictor of a worst clinical outcome, even during a short term follow-up and may help in patients risk stratification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343603     DOI: 10.1016/j.thromres.2005.10.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  17 in total

Review 1.  Platelet hyperreactivity: predictive and intrinsic properties.

Authors:  Paul F Bray
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

Review 2.  Current developments in anti-platelet therapy.

Authors:  Florian B Mayr; Bernd Jilma
Journal:  Wien Med Wochenschr       Date:  2006-09

3.  Human genome-wide association and mouse knockout approaches identify platelet supervillin as an inhibitor of thrombus formation under shear stress.

Authors:  Leonard C Edelstein; Elizabeth J Luna; Ian B Gibson; Molly Bray; Ying Jin; Altaf Kondkar; Srikanth Nagalla; Nacima Hadjout-Rabi; Tara C Smith; Daniel Covarrubias; Stephen N Jones; Firdos Ahmad; Moritz Stolla; Xianguo Kong; Zhiyou Fang; Wolfgang Bergmeier; Chad Shaw; Suzanne M Leal; Paul F Bray
Journal:  Circulation       Date:  2012-05-01       Impact factor: 29.690

4.  Role of Dipyrone in the High On-Treatment Platelet Reactivity amongst Acetylsalicylic Acid-Treated Patients Undergoing Peripheral Artery Revascularisation.

Authors:  Jan Hartinger; Robert Novotny; Jana Bilkova; Tomas Kvasnicka; Petr Mitas; Martin Sima; Jaroslav Hlubocky; Jan Kvasnicka; Ondrej Slanar; Jaroslav Lindner
Journal:  Med Princ Pract       Date:  2018-05-13       Impact factor: 1.927

5.  Air pollution related prothrombotic changes in persons with diabetes.

Authors:  Lotte Jacobs; Jan Emmerechts; Chantal Mathieu; Marc F Hoylaerts; Frans Fierens; Peter H Hoet; Benoit Nemery; Tim S Nawrot
Journal:  Environ Health Perspect       Date:  2010-02       Impact factor: 9.031

Review 6.  Aspirin and clopidogrel response variability: review of the published literature.

Authors:  Angela D Ferguson; Hisham Dokainish; Nasser Lakkis
Journal:  Tex Heart Inst J       Date:  2008

7.  Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain.

Authors:  Andrew D Atiemo; Ladina S Ng'Alla; Dhananjay Vaidya; Marlene S Williams
Journal:  J Thromb Thrombolysis       Date:  2007-06-07       Impact factor: 2.300

8.  Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.

Authors:  Hong-Chang Zhu; Yi Li; Shao-Yi Guan; Jing Li; Xiao-Zeng Wang; Quan-Min Jing; Zu-Lu Wang; Ya-Ling Han
Journal:  J Geriatr Cardiol       Date:  2015-01       Impact factor: 3.327

9.  High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial).

Authors:  Alf-Åge R Pettersen; Ingebjørg Seljeflot; Michael Abdelnoor; Harald Arnesen
Journal:  J Am Heart Assoc       Date:  2012-06-22       Impact factor: 5.501

Review 10.  Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.

Authors:  Max-Paul Winter; Marek Koziński; Jacek Kubica; Daniel Aradi; Jolanta M Siller-Matula
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-01-12       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.